Company intelligence / Profile preview

Talisman Therapeutics

Cambridge, England, United Kingdomtalisman-therapeutics.com ↗

Ownership: Private
Employees: ~13
Development stage: Other

Overview

Talisman Therapeutics has developed a proprietary iPSC-based platform for modeling neurodegenerative diseases, with a focus on Alzheimer’s. Their approach enables more relevant compound identification and de-risks drug development. Internal programs are in preclinical stages, targeting lysosome biology, pathogenic protein reduction, and microglial health. The company also partners with biotechs and pharma to support external neuroscience discovery efforts. No clinical results have been published.

Therapeutic areas: Neurology
Modalities: Cell therapyInduced pluripotent stem cell derived therapy (iPSC)
Industry: Biotech

Partnerships

Several large pharmaceutical companies as customers/partners for R&D servicesBiotechs and venture capital-backed companies for preclinical discovery support

Beyond the preview

Go deeper on Talisman Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Talisman Therapeutics.